Navigation Links
iPierian Closes $22 Million Series B Financing Led By Google Ventures
Date:7/8/2010

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing.  The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures.  All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. This financing will allow the company to drive its programs into the clinic, while securing pharmaceutical partnerships.  The Series B financing brings the total amount of equity capital raised by iPierian to $54 million since its inception in 2007.

Krishna Yeshwant, M.D., a partner at Google Ventures, will join the iPierian Board of Directors.  "iPierian's work with iPSCs is incredibly exciting.  The company has perfected a difficult technology and is making excellent progress in finding new therapeutics to treat serious diseases," said Dr. Yeshwant.  "The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will dramatically improve the drug discovery and development process, and we look forward to helping them accomplish their mission."

Corey Goodman, Ph.D., chairman of the iPierian Board, commented, "We are pleased to welcome our new investors.  Our rapid scientific progress is allowing us to harness iPS technology as a research platform to identify novel therapeutics for patients with major unmet medical needs."

In conjunction with the closing of the Series B financing, Michael C. Venuti, Ph.D., president and chief scientific officer since February 2010, will assume the role of chief executive officer, and will join the Board of Directors. John P. Walker, who has been the CEO of iPierian since February 2009, is stepping down for personal reasons from his position as CEO and member of the Board of Directors and will remain employed by the company as a senior advisor.

"We thank John for his inspired leadership, and I personally value John's continued input as a senior advisor," said Dr. Venuti.  "Under his leadership, the company has emerged as the leader in utilizing the iPSC platform for drug discovery, as evidenced by industrializing the technology, the significant progress with three proprietary programs, and recently being awarded research grants from the California Institute for Regenerative Medicine (CIRM) and the National Institutes of Health (NIH)."

Mr. Walker added, "I am confident in handing over the day-to-day responsibilities of the company to Mike.  He has demonstrated an enviable track record in drug discovery, management and business development, all of which will be important in building on the excitement of this paradigm shift in drug discovery."

For additional information about Dr. Krishna Yeshwant and Google Ventures, please visit www.google.com/ventures.  

About iPierian

iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and directed differentiation of patient cells for the discovery and development of new therapeutics. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease, in addition to a broad therapeutic area program intended for partnering in metabolic disease.  

The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gladstone Institute and The University of California, San Francisco.  Our scientific founders are George Q. Daley, M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D. all of the Harvard Stem Cell Institute, and Deepak Srivastava, M.D., of the Gladstone Institute and UCSF. 

iPierian is located in South San Francisco, California.  For more information, please visit www.ipierian.com.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
2. BioVascular Inc. Closes $10.87 Million Series C Financing
3. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
4. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
5. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
6. Curemark Closes Series A Financing
7. Blue Belt Technologies, Inc. Closes Series A Financing
8. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
9. American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008
10. Keraderm Closes on $2.5 Million Investment from NewVa Capital Partners, LP
11. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):